← All trials
NCT04421664
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2020
- Primary completion
- Jul 1, 2020
- Completion date
- Aug 26, 2020
- First posted
- Jun 9, 2020
- Last posted
- Jun 9, 2020
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- McGill UniversityLead sponsor
- University of ManitobaCollaborator
- McGill UniversityOverall official - principal investigator
- McGill UniversityReponsible party - principal investigator
- McMaster UniversityCollaborator
- University of AlbertaCollaborator
- University of British ColumbiaCollaborator
- Eastern Health, CanadaCollaborator
- University of MinnesotaCollaborator
- University of Western OntarioCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.